Cushing’s Disease Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Corcept Therapeutics, Sparrow Pharma, Recordati, Xeris Pharma, H. Lundbeck

Posted on
by

Cushing’s Disease Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Corcept Therapeutics, Sparrow Pharma, Recordati, Xeris Pharma, H. Lundbeck
The Key Cushing’s Disease Companies in the market include – Corcept Therapeutics, Sparrow Pharmaceuticals, Recordati, Xeris Pharmaceuticals, H. Lundbeck, Stero Therapeutics, Crinetics Pharmaceuticals, and others.

 

DelveInsight’s “Cushing’s Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Cushing’s Disease, historical and forecasted epidemiology as well as the Cushing’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Cushing’s Disease, offering comprehensive insights into the Cushing’s Disease revenue trends, prevalence, and treatment landscape. The report delves into key Cushing’s Disease statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Cushing’s Disease therapies. Additionally, we cover the landscape of Cushing’s Disease clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Cushing’s Disease treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Cushing’s Disease space.

 

To Know in detail about the Cushing’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cushing’s Disease Market Forecast

 

Some of the key facts of the Cushing’s Disease Market Report:

  • The Cushing’s Disease market size was valued ~USD 1,089 million in 2025 and is anticipated to grow with a significant CAGR of 5.90% during the study period (2020-2034).

  • In December 2024, Corcept Therapeutics has filed a New Drug Application (NDA) with the U.S. FDA for relacorilant, a selective cortisol modulator intended to treat patients with endogenous hypercortisolism (Cushing’s syndrome).

  • In October 2024, Sparrow Pharmaceuticals announced that its drug clofutriben has been granted FDA Orphan Drug Designation for treating endogenous Cushing’s syndrome.

  • In 2024, the United States held the largest market share among the 7MM countries, amounting to approximately USD 930 million.

  • In 2024, the EU4 and the UK together represented around USD 85 million of the market, with Germany holding the largest share within this region.

  • In 2024, Japan’s Cushing’s disease market was valued at approximately USD 45 million and is projected to grow at a notable CAGR between 2025 and 2034.

  • In 2024, Mifepristone (KORLYM and its generics) generated the highest revenue among all existing Cushing’s disease therapies in the United States.

  • Key Cushing’s Disease Companies: Corcept Therapeutics, Sparrow Pharmaceuticals, Recordati, Xeris Pharmaceuticals, H. Lundbeck, Stero Therapeutics, Crinetics Pharmaceuticals, and others

  • Key Cushing’s Disease Therapies: Relacorilant (CORT125134), Clofutriben (SPI-62), ISTURISA (osilodrostat), RECORLEV (levoketoconazole), SIGNIFOR (pasireotide), KORLYM* (mifepristone), Lu AG13909*, ST-002***, Atumelnant(CRN04894), and others

  • The Cushing’s Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cushing’s Disease pipeline products will significantly revolutionize the Cushing’s Disease market dynamics.

  • In 2024, the United States had an estimated 19,950 diagnosed prevalent cases of Cushing’s disease, with numbers expected to rise between 2025 and 2034.

  • In 2024, the diagnosed prevalent cases of Cushing’s disease in the US were around 4,450 for males and 15,500 for females.

  • In 2024, the EU4 and the UK recorded roughly 12,400 diagnosed prevalent cases of Cushing’s disease, with around 2,650 cases in males and 9,750 cases in females.

  • In 2024, age-specific data in the US showed that adults accounted for the majority of diagnosed Cushing’s disease cases, with approximately 17,950 cases, while children had around 2,000 cases. These numbers are expected to rise between 2025 and 2034.

  • Endogenous Cushing’s syndrome is categorized into ACTH-dependent and ACTH-independent types. ACTH-dependent cases make up 80–85% of all instances, with 75–80% of these resulting from ACTH secretion by a pituitary adenoma, known as Cushing’s disease.

  • In 2024, the 7MM had approximately 37,100 diagnosed prevalent cases of Cushing’s disease, with the United States representing the largest share of these cases.In 2024, across the 7MM, females had a higher number of diagnosed prevalent cases of Cushing’s disease compared to males.

  • Diagnosing Cushing’s disease is especially difficult because of its rarity, overlapping symptoms with other disorders, and varied clinical presentation. Only 40–60% of patients show a detectable tumor on standard MRI, and the average time to diagnosis is about seven years.

  • The projected five-year survival rate for individuals with untreated Cushing’s disease is approximately 50%.

  • SIGNIFOR and SIGNIFOR LAR are the only therapies specifically approved for Cushing’s disease, while ISTURISA is indicated for treating Cushing’s disease in the US and for endogenous Cushing’s syndrome in the EU and Japan.

  • “The Cushing’s disease pipeline includes several promising therapies in mid- and late-stage development. Notable candidates are Relacorilant (CORT125134) from Corcept Therapeutics, Clofutriben (SPI-62) from Sparrow Pharmaceuticals, and Atumelnant (CRN04894) from Crinetics Pharmaceuticals.

 

Cushing’s Disease Overview

Cushing’s Disease is a rare endocrine disorder caused by an overproduction of the hormone cortisol, usually due to a pituitary gland tumor that secretes excessive adrenocorticotropic hormone (ACTH). This excess ACTH stimulates the adrenal glands, leading to elevated cortisol levels in the body.

 

Get a Free sample for the Cushing’s Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/cushings-disease-market

 

Cushing’s Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Cushing’s Disease Epidemiology Segmentation:

The Cushing’s Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Cushing’s Disease

  • Prevalent Cases of Cushing’s Disease by severity

  • Gender-specific Prevalence of Cushing’s Disease

  • Diagnosed Cases of Episodic and Chronic Cushing’s Disease

 

Download the report to understand which factors are driving Cushing’s Disease epidemiology trends @ Cushing’s Disease Epidemiology Forecast

 

Cushing’s Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cushing’s Disease market or expected to get launched during the study period. The analysis covers Cushing’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cushing’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Cushing’s Disease Therapies and Key Companies

  • Relacorilant (CORT125134): Corcept Therapeutics

  • Clofutriben (SPI-62): Sparrow Pharmaceuticals

  • ISTURISA (osilodrostat): Recordati

  • RECORLEV (levoketoconazole): Xeris Pharmaceuticals

  • SIGNIFOR (pasireotide): Recordati

  • KORLYM* (mifepristone): Corcept Therapeutics

  • Lu AG13909*: H. Lundbeck

  • ST-002***: Stero Therapeutics

  • Atumelnant(CRN04894): Crinetics Pharmaceuticals

 

Discover more about therapies set to grab major Cushing’s Disease market share @ Cushing’s Disease Treatment Landscape

 

Cushing’s Disease Market Drivers

  • Rising prevalence and diagnosed cases of Cushing’s disease globally, expanding the patient pool.

  • Increasing awareness among physicians and patients, leading to earlier diagnosis and treatment.

  • Advances in diagnostic techniques, such as improved imaging and biochemical tests, enabling better disease detection.

  • Ongoing development of novel therapies, including selective glucocorticoid receptor antagonists and targeted drugs.

  • Supportive regulatory environment, including orphan drug designation, incentivizing pharmaceutical innovation.

 

Cushing’s Disease Market Barriers

  • Complexity of diagnosis, due to symptom overlap with other conditions and the disease’s rarity, causing delays in treatment.

  • Limited approved therapies, restricting available treatment options for patients.

  • High cost of treatment, especially for advanced or long-term therapies.

  • Small patient population, which can limit commercial attractiveness for new drug development.

  • Potential side effects and long-term complications of current therapies, impacting patient adherence and outcomes.

 

Scope of the Cushing’s Disease Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Cushing’s Disease Companies: Corcept Therapeutics, Sparrow Pharmaceuticals, Recordati, Xeris Pharmaceuticals, Corcept Therapeutics, H. Lundbeck, Stero Therapeutics, Crinetics Pharmaceuticals, and others

  • Key Cushing’s Disease Therapies: Relacorilant (CORT125134), Clofutriben (SPI-62), ISTURISA (osilodrostat), RECORLEV (levoketoconazole), SIGNIFOR (pasireotide), KORLYM* (mifepristone), Lu AG13909*, ST-002***, Atumelnant(CRN04894), and others

  • Cushing’s Disease Therapeutic Assessment: Cushing’s Disease current marketed and Cushing’s Disease emerging therapies

  • Cushing’s Disease Market Dynamics: Cushing’s Disease market drivers and Cushing’s Disease market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Cushing’s Disease Unmet Needs, KOL’s views, Analyst’s views, Cushing’s Disease Market Access and Reimbursement

 

To know more about Cushing’s Disease companies working in the treatment market, visit @ Cushing’s Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Cushing’s Disease Market Report Introduction

2. Executive Summary for Cushing’s Disease

3. SWOT analysis of Cushing’s Disease

4. Cushing’s Disease Patient Share (%) Overview at a Glance

5. Cushing’s Disease Market Overview at a Glance

6. Cushing’s Disease Disease Background and Overview

7. Cushing’s Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Cushing’s Disease

9. Cushing’s Disease Current Treatment and Medical Practices

10. Cushing’s Disease Unmet Needs

11. Cushing’s Disease Emerging Therapies

12. Cushing’s Disease Market Outlook

13. Country-Wise Cushing’s Disease Market Analysis (2020–2034)

14. Cushing’s Disease Market Access and Reimbursement of Therapies

15. Cushing’s Disease Market Drivers

16. Cushing’s Disease Market Barriers

17. Cushing’s Disease Appendix

18. Cushing’s Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/